COGENTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COGENTIN (COGENTIN).
Centrally acting anticholinergic agent; blocks muscarinic acetylcholine receptors in the basal ganglia, restoring cholinergic-dopaminergic balance.
| Metabolism | Primarily hepatic via hydroxylation and N-oxidation; CYP enzymes not well characterized. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; approximately 40-50% excreted in urine as unchanged drug, with the remainder as metabolites. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 12-24 hours in adults; may be prolonged in elderly or patients with hepatic impairment. Clinical context: Steady-state achieved in 2-3 days with regular dosing. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 1.0 L/kg, indicating extensive tissue distribution, particularly into brain and skeletal muscle. |
| Bioavailability | Oral bioavailability is approximately 80% (range 60-90%), with significant first-pass metabolism. Intramuscular bioavailability is near 100%. |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 15-30 minutes; Intravenous: within 5-10 minutes. Clinical effect is maximal within 2 hours. |
| Duration of Action | Oral: 6-12 hours; Intramuscular/Intravenous: 6-8 hours. Duration may be extended in elderly or hepatic impairment. Note: Anticholinergic effects may persist for up to 24 hours. |
Initial: 1 mg orally once daily, increase gradually; usual maintenance: 1-2 mg twice daily; range 0.5-6 mg/day. Also 1-2 mg IM or IV every 4-6 hours for acute dystonia.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment. GFR <10 mL/min: consider dose reduction or extended interval. |
| Liver impairment | No specific guidelines; use with caution in hepatic impairment. Child-Pugh Class C: consider dose reduction. |
| Pediatric use | 3-12 years: 0.02-0.05 mg/kg/dose orally twice daily; maximum 2 mg/day. For acute dystonia: 0.02-0.05 mg/kg IM or IV, may repeat after 30 minutes. |
| Geriatric use | Initiate at 0.5 mg once or twice daily; increase slowly; monitor for confusion, cognitive impairment, and anticholinergic side effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COGENTIN (COGENTIN).
| Breastfeeding | Benztropine (COGENTIN) is excreted into breast milk; M/P ratio unknown. Due to potential for anticholinergic effects in the infant (e.g., agitation, constipation, drowsiness), use with caution, especially in neonates. Consider alternative agents if possible. |
| Teratogenic Risk | First trimester: Limited human data, but animal studies suggest no increased risk of major malformations; anticholinergic effects may cause fetal tachycardia. Second trimester: No specific risks identified; monitor for maternal anticholinergic toxicity. Third trimester: Risk of neonatal anticholinergic effects (e.g., ileus, tachycardia, urinary retention) if used near term. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to benztropine","Narrow-angle glaucoma","Pyloric obstruction","Prostatic hypertrophy","Myasthenia gravis"]
| Precautions | ["May cause drowsiness, confusion, and hallucinations; use with caution in elderly.","Avoid abrupt discontinuation to prevent withdrawal symptoms.","May reduce sweating and increase risk of heat stroke."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and anticholinergic symptoms (dry mouth, blurred vision, constipation, urinary retention). Assess fetal heart rate for tachycardia. In third trimester, monitor neonatal for anticholinergic withdrawal or toxicity signs. |
| Fertility Effects | Not known to significantly impair fertility. Anticholinergic effects may theoretically affect cervical mucus or sperm motility, but no confirmed data. No evidence of adverse effects on human reproduction. |